APA (7th ed.) Citation

KH, K., SB, C., SH, L., HS, B., CS, H., MG, L., . . . SH, H. (2023). A novel defined TLR3 agonist as an effective vaccine adjuvant. Frontiers in immunology, 14, 1075291. https://doi.org/10.3389/fimmu.2023.1075291

Chicago Style (17th ed.) Citation

KH, Ko, Cha SB, Lee SH, Bae HS, Ham CS, Lee MG, Kim DH, and Han SH. "A Novel Defined TLR3 Agonist as an Effective Vaccine Adjuvant." Frontiers in Immunology 14 (2023): 1075291. https://doi.org/10.3389/fimmu.2023.1075291.

MLA (9th ed.) Citation

KH, Ko, et al. "A Novel Defined TLR3 Agonist as an Effective Vaccine Adjuvant." Frontiers in Immunology, vol. 14, 2023, p. 1075291, https://doi.org/10.3389/fimmu.2023.1075291.